T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
Status:
Withdrawn
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
This is a unique dose-escalation trial that will titrate doses of umbilical cord blood (UCB)
Treg and CD3+ Teff cells with the goal of infusing as many CD3+ Teff cells as possible
without conferring grade II-IV acute graft-versus-host disease (GVHD).
In this study, the investigators propose to add UCB Treg and UCB CD3+ Teff cells to the two
TCD UCB donor units with the goal of transplanting as many CD3+ Teff cells as possible
without reintroducing risk of acute GVHD. The investigators hypothesize that Treg will permit
the reintroduction of CD3+ Teff cells that will provide a bridge while awaiting HSC T cell
recovery long term. The co-infusion of Treg will prevent GVHD without the need for prolonged
pharmacologic immunosuppression.